Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
SAN DIEGO, Nov. 09, 2016 -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the Stifel 2016 Healthcare Conference in New York at 8:45 a.m. ET on Wednesday, November 16, 2016.
An audio webcast and copy of the presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
MEDIA: David Schull Russo Partners, LLC (858) 717-2310 [email protected] INVESTORS: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637 [email protected]
